title: [Systemic treatment of melanoma. Current clinical trials].
abstract: Malignant melanoma is one of the most common cancers accounting for 4-5% of all human malignancies and steadily increasing in incidence. The medical management of melanoma patients in Germany can be regarded as largely standardized based upon interdisciplinary guide lines. The results of adjuvant and especially palliative treatment of melanoma are unsatisfactory. Thus there is an urgent need for controlled clinical trials in order to optimize standard treatment approaches and to evaluate new drugs. The treatment of patients affected with high risk or metastatic melanoma within those clinical trials should be standard of care. This overview delineates the most important clinical trials currently conducted or planned in the adjuvant and palliative setting of melanoma treatment.
authors.affiliation: Schwerpunktbereich Dermato-Onkologie und Operative Dermatologie, Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein - Campus Kiel, Kiel, Deutschland. ahauschild@dermatology.uni-kiel.de
authors.forename: A
authors.initials: A
authors.lastname: Hauschild
authors.forename: K
authors.initials: K
authors.lastname: Rass
authors.forename: W
authors.initials: W
authors.lastname: Tilgen
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D016503:Drug Delivery Systems; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D010166:Palliative Care; D016032:Randomized Controlled Trials as Topic; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational